Guide

Biosimilars pipeline report: A guide for understanding the growing market 

To date, there have been 59 approvals and 41 launches in the U.S. biosimilars market. 
Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.

To view and read this report, please fill out the form. 

Related resources

Article

From AI to regulatory layering and convergence: Key takeaways from RAPS Euro Convergence 2026

Article

How U.S. pricing reform is reshaping global market dynamics

Guide

Cell and gene therapy playbook for payer engagement: Translating payer expectations into actionable market access strategies

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.
abstract